[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,975
Citations 0
Editorial
November 24, 2015

Anti-VEGF Pharmacotherapy as an Alternative to Panretinal Laser Photocoagulation for Proliferative Diabetic Retinopathy

Author Affiliations
  • 1Emory Eye Clinic, Department of Ophthalmology, Emory University, Atlanta, Georgia
JAMA. 2015;314(20):2135-2136. doi:10.1001/jama.2015.15409

From 1976 to 1981, the results of the Diabetic Retinopathy Study identified that panretinal laser photocoagulation (PRP) for high-risk proliferative diabetic retinopathy (PDR) reduced the rate of severe visual acuity loss by more than 50% compared with the natural history of the disease.1,2 The Diabetic Retinopathy Study identified 4 key risk features of PDR (retinal neovascularization [NV]; NV within 1 disc diameter of the optic disc [NVD]; severe NV [NVD >¼ to ⅓ disc diameters or NV elsewhere >½ disc diameter]; and preretinal or vitreous hemorrhage) and indicated that the presence of 3 or more risk factors constituted high-risk characteristics for developing severe vision loss.3 The results of the Diabetic Retinopathy Study have served as the basis for the accepted standard of care in the management of PDR for decades.

First Page Preview View Large
First page PDF preview
First page PDF preview
×